[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360597-105":59,"doc-detail-360597-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multifunctional-and-dual-targeting-polymeric-prodrug-nanomicelles-against-tamoxifen-resistant-breast-cancer","Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer","","Tamoxifen resistance persists as a major barrier in estrogen receptor (ER)-positive breast cancer, driven by EGFR overexpression, TAM metabolic variability, P-glycoprotein (P-gp)–mediated drug efflux, and poor tumor-specific drug delivery. A multifunctional, dual-targeting polymeric prodrug nanomicelle platform was developed by self-assembly of a HA-ester precursor (HA-4-hydroxytamoxifen) with TPGS, loading dasatinib (DAS). The system targets TAM-resistant tumors via HA/4-OH-TAM while releasing DAS, 4-OH-TAM, and TPGS in the tumor microenvironment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multifunctional-and-dual-targeting-polymeric-prodrug-nanomicelles-against-tamoxifen-resistant-breast-cancer/360597/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multifunctional-and-dual-targeting-polymeric-prodrug-nanomicelles-against-tamoxifen-resistant-breast-cancer/360597.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What causes tamoxifen resistance in ER-positive breast cancer?","Question",{"text":112,"@type":113},"Resistance is associated with EGFR overexpression, variations in TAM metabolism, increased P-gp–mediated drug efflux, and insufficient tumor-specific drug delivery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the designed nanomicelle platform work?",{"text":117,"@type":113},"The platform is self-assembled from a HA-4-hydroxytamoxifen ester precursor and TPGS, loaded with dasatinib, enabling dual targeting and tumor microenvironment–triggered release of DAS, 4-OH-TAM, and TPGS.",{"name":119,"@type":110,"acceptedAnswer":120},"What was observed about drug release under different pH conditions?",{"text":121,"@type":113},"Drug release was pH-sensitive; cumulative release rates of 4-OH-TAM and DAS within 48 h at pH 5.0 were significantly higher than at pH 6.0 and 7.4.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360597,1790179702,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMultifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer  \nQi-lin Ji1, Ying Zeng1, Hao Zhou1, Qing-bin Wang1, Run-ying Zhou1, Jing-jing Zhang1,2􀀍 & Xiu Wang1􀀍  \nTamoxifen (TAM) resistance remains a significant challenge in treating estrogen receptor (ER) -positive breast cancer. Overexpression of epidermal growth factor receptor (EGFR), variations inTAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer. The lack of specific drug distribution to tumors further complicates the treatment of TAM-resistant breast cancer. Simultaneously addressing these four factors—EGFR overexpression, TAM metabolic variations, P-gp-mediated drug efflux, and poor tumor-specific delivery—can significantly enhance the treatment of TAM-resistant breast cancer. This study aimed to design a multifunctional and dual-targeting polymeric prodrug nanomicelle platform. The platform was self-assembled using the amphipathic precursor drug material [hyaluronic acid (HA)-4-hydroxytamoxifen (4-OH-TAM) ester (esterified by HA and 4-OH-TAM)] and D-α-tocopheryl polyethylene glycol succinate (TPGS), loaded with dasatinib (DAS). The nanosystem could target breast cancer mediated by HA and 4-OH-TAM, releasing DAS, 4-OH-TAM, and TPGS in tumor microenvironment. 4-OH-TAM, an active metabolite of TAM, substantially impacted TAM-resistant breast cancer by avoiding the metabolic differences inTAM. TPGS inhibited P-gp-mediated drug efflux, thereby increasing intracellular accumulation of DAS and enhancing its inhibitory effect on TAMresistant breast cancer cells. The results showed that the nanomicelles released drugs in a pH-sensitive manner. The cumulative release rates of 4-OH-TAM and DAS were (72.73 ± 3.99)% and (78.39 ± 3.09)%, respectively, within 48 h in a pH 5.0 solution, significantly higher than those in pH 6.0 and 7.4 solutions. The findings regarding cellular uptake and biodistribution indicated that the nanomicelles exhibited effective targeting capabilities toward TAM-resistant breast cancer. Both in vitro and in vivo studies demonstrated a marked effect of nanomicelles against TAM-resistant breast cancer through  \nthe targeting characteristic of nanoparticles and the actions of drugs (4-OH-TAM, DAS, andTPGS). The study provides fresh perspectives and suggestions for the clinical treatment of TAM-resistant breast cancer.  \nKeywords Breast cancer, Dasatinib, Dual targeting, Nanomicelles, Tamoxifen resistance  \nBreast cancer is a leading health concern among women due to its high mortality and morbidity rates1,2. Approximately 70–80% of breast cancers are positive for the expression of estrogen receptor (ER)3,4. The expression of ER is a defining feature, which executes a transcriptional program driving proliferation and expansion of the mammary epithelia during puberty5–7. Hence, ER targeting has become the cornerstone of treatment in both early-stage and metastatic ER+ breast cancers. Endocrine therapy represented by tamoxifen (TAM) has considerably reduced recurrence and mortality due to breast cancer. However, acquired resistance to this treatment remains a major challenge8,9.  \nSeveral factors lead to TAM resistance. Epidermal growth factor receptor (EGFR) is a receptor that mediates epidermal growth factor–induced cell proliferation and signaling. The interaction between EGFRand ER signaling is closely related to tumor occurrence, development, and drug resistance in breast cancer10. The activation of EGFR can make ER-positive breast cancer cells resistant to endocrine therapy drugs such as  \n1Bengbu Medical University, 2600 Donghaidadao, Bengbu 233030, China. 2Department of Oncology, The First Affiliated Hospital of Bengbu Medical University, 287 Changhuailu, Bengbu 233004, China. 􀀍 email:  \n[zjjahbb@163.com](zjjahbb@163.com); [b","cbCaipjMK5vXrLKr","https://ap.wps.com/l/cbCaipjMK5vXrLKr","pdf",3196314,13,"English","# Introduction\n## Background: ER+ breast cancer and tamoxifen resistance\n## Key mechanisms: EGFR, P-gp, and TAM metabolism\n# Design of the nanomicelle platform\n## Composition and self-assembly strategy\n# Drug release and biological evaluation\n## pH-sensitive release behavior\n## Cellular uptake and biodistribution\n# Therapeutic implications","[{\"question\":\"What causes tamoxifen resistance in ER-positive breast cancer?\",\"answer\":\"Resistance is associated with EGFR overexpression, variations in TAM metabolism, increased P-gp–mediated drug efflux, and insufficient tumor-specific drug delivery.\"},{\"question\":\"How does the designed nanomicelle platform work?\",\"answer\":\"The platform is self-assembled from a HA-4-hydroxytamoxifen ester precursor and TPGS, loaded with dasatinib, enabling dual targeting and tumor microenvironment–triggered release of DAS, 4-OH-TAM, and TPGS.\"},{\"question\":\"What was observed about drug release under different pH conditions?\",\"answer\":\"Drug release was pH-sensitive; cumulative release rates of 4-OH-TAM and DAS within 48 h at pH 5.0 were significantly higher than at pH 6.0 and 7.4.\"}]","Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer | PDF",1790140652,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cbfa3ee64fb070984c54238f17fd04b.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93b39daf628290a91f1f14b92d951b30.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f612948176fc72257ceccc0e343a087.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c731da325e6e7780a4f94a384f7867bc.webp",980,1287]